Seminars in Oncology 6 tes ELSEVIER AUTHOR INDEX Aiken, R.D., 2¢ Goolsby T.V., 139 Armstrong Gray, P.J., 367, 436 Atkins, M.B Green, M.D., 2 CadOpOoUlosS Grever, M.R., 210 664 sain, S., 15 Gribben, J., 220 Baselga, J., 369 Belldegrun, A.S., 563, 607 Haider, S., 121 3enhadji, K.A., 466 Hamblin, T.J., 230 Han, H., 513 Hausheer, F.H., 15 Houlston, R.S., 195 Huang, Ru Chih C., 479 Hurley, L.H., 498 3rown, R.J., 657 3runo, D., 696 Jacobsohn, K.} Sukowski, R.M., 596 Jaeckle, K A. 312 syrd, J.C., 149, 157, 210 ames, W.D., 86 Byrne, I.N., 307 ohnson, M., 672 Jordan, V.C., 6 1 aligaris-Cappio, F., 150 Calin, G.A., 167 Kaelin Jr, W.G., 588 alvo, E 421 alvo, F., 466 arter, C., 392 atovsky, D., 195 Kim chan, K., 642 Ko, J., hang, C.C Koh, M.Y houeiri, T.K Krishnan, B., ordera, I Kubler, H rawford, J Kumar Pal, S., roce, C.M., Kuo, T., 299 Cullinan, S.B., Cvitkovic, E Daly, M.B., Daniel, D Darnell, R.B Davidson, N.I Davidson, R de Jonge, M.]J DeAngelis, L.M., Dearden ( Djelloul, S Ma, C.X Maiutes, Ef MM cDermott McLaughlin,J Faivre, S., 407 Feeney, K.J Figlin, R.A Mold, D Floyd, J., 50 Morris, G.J Fox, K., 664 Morrison, \ usses, S., Ghia, P., 150 Ghoul, A., 466 Glass, J., 342 Gollob, J.A., 392 Seminars in Oncology ELSEVIER SUBJECT INDEX Angiogenesis inhibitors, for renal cell carcinoma (Continued anti-VEGF antibody, 596-599 BAY 43-9006, 601-602 controversies, 603-604 GW786034, 602-603 PTK 787/ZK222584, 602 SU11248, 599-601 VEGF-trap, 599 Angiogenic cytokines, biologic implications in chroriic lymphocytic leuke- 78-179 Angiogenic factors in hematopoietic cell development and hematologic malignancy) serum/plasma levels in chronic lymphocytic leukemia, 176-177 Anthracyclines cardiotoxicity of dexrazoxane, 4-5 epirubicin, 4 liposomal doxorubicin formulations, 5 monitoring during treatment, 5-7 pediatric considerations, 3-4 prognosis and treatment, 10 scheduling, 4 for management of f chemotherapy extravasation, 141-142 Anti-Bcl-2 agents, for targeted cancer therapy, 367, 449-456 antisense oligonucleotides, 450-451 miRNAs, 452 non-peptide antagonists, 452-453 peptide antagonists, 452 \ntibodies ffoorr ftllauiadaarraabhdiinnee -retofry actotrony chhry onic llywmmpnnho cytivic ;i nttrraatthphee cal, for neoplt ast, ic} ,m en>iY nginiiosti its , 23020() aneoplastic encephalomyelitis see Chemotherapy ts, for menopausal vasomotor symptoms in breast cancer sur vivors. 699 -EGFR agents, for linical biomarker-dr implications for developme integration with conventional therapies, 377-378 low-molecular-weight EGFR tyrosine kinase inhibitors mechanisms of action monoclonal antibodies, 372 opnttiimmaal l |p iollooggiiccaall dose,> 9/0 5 with other targeted therapies rational biomarker development A\ nttlieerm eti>tc s, inn canY cer chL emmom the} rapy7 , nyePulrr ototoxysi cityt ol f \nti-epileptic drugs, for brain tumor patients C hoice, effectiveness, and adverse reactions, 335-339 interactions with chemotherapy and glucocorticoids prophylactic use of, 334-335 Anti-estrogens chemotherapy-related hepatotoxicity of, 59 role in cancer prog on for targeted cancer therapy, +72 AAl‘ n ngiogenesis inh Antigenic peptide vaccines, for renal cell carcinoma, 620 adjuvant therapy, 580 \ntigen-presenting cells AGO13736, artificial, and vaccines for renal cell carcinoma, 6 > Subject index Antigen-presenting cells (Continued nesis of autoimmunity in chroni Antigens, ana b-cell chronic lymph Anti-HER2 a t targeted canc monoclonal antibodies reast cancer, 637 evolution olf resistance to, 637-638 Antihypertensive agents, and renal cell carcinoma Anti-M agents, for targeted cancer thet Antimetaboli in cancer chemotherapy} cytarabine renal toxici Antimicrobial prophylaxis, in chronic lymphocytic l 4 LUDL e fi or - targeted } cancer iti-PKC agen AAlp optosis induced in adjuvant therapy tor postmenopausal 1 alter 2 to years of tamoxiten, 674-67 clinical trials, 674 decision-making and future directions, 677 Subject index en nn ee EnnEEEISSSE Breast cancer (Continued ) biology and growth of antihormonal therapy, 637 coactivators and corepressors, 634 estrogen receptor activation, 638 estrogen receptor alfa in, 633 estrogen receptor beta in, 633-634 estrogen receptor in, 631-632 estrogen receptor signal transduction evolution of antihormone resistance, 637-6 toxicity, 6 gene activation by estrogen receptor, 634-635 1ingeal, in mosis of neoplastic meningi 14 HER growth factor receptors in, 636 3irt-Hogg-Dubé syndrome, genetic basis of, 547-5¢ heterogenous nature, 632 3isindolmaleimi stone deacetylases and, 634 cancer survi- molecular mechanisms, 632 progesterone receptor in, 0 chemoprevention in high-risk women benign lesions and genetic predisposition, 6 guidelines, 644-645 ongoing studies, 645 patient monitoring, 645 tamoxifen, 642-643 esis in estrogen therapy for hormonal therapy for, 629-630 role of Her-2/neu status, 681-686 locally advanced, neoadjuvant endoctr ACOSOG Z1031 Trial, khy; iommaarrkee r anal|y sis in, 65532 -65454 as sh} ort-term surrogate to predi} ct long-term outcomes, 605- 3 fen, 650-651 l-generation aromatase inhibitors, 651-652 v chemotherapy, 65 1 postmenopausal women aromatase inhibitors for, 673-679 tamoxiten for, 672-673 al women lity preservation and impact of subsequent pregnancy survivors, treatment of menopausal symptoms in, 696-704 ‘diovascular disease, 703 osteoporosis, 700-702 urogen atrophy, 7 vasomotor symptoms, ¢ imab cardiotoxicit Bronchospasm, chemotherapy-related, 98 Bryostatins, for targeted cancer therapy, Budd-Chiari syndrome, chemot Se iccordinp ve propnoeis? 300 Busulfan, chemotherapy-related toxicity eae ae prophylactic cranial irradiation, hepatotoxicity, lung injury, 101 achectic myopathy, paraneoplastic, 2+ 9922 alcium/magnesium infusions, for acute oxaliplatin neuropathy alphostins, for targeted cancer ampath-1H, see Alemtuzumab ancer epigenetic deregul of kidney, see Kidney neoplasms progression, role of angiogenesis, 174-175 targeted therapies for, 367-368, 408-409 anti-Bcl-2 agents, 449-456 antisense oligonucleotides, 450-451 surgical management, miRNAs. 452 ; ; Brainstem encephal non-peptide antagonists, 452-453 Breast cancer peptide antagonists, 452 adjuv ant hormonal t menopausal women anti-EGFR agents ovarian ablation and suppression, 658-660 clinical biomarker-driven studies, 376-377 recommendations from consensus meetings, 660 implications for development 375-376 research directions, 660-662 integration with conventional therapies, 377-378 tamoxifen, 657 low-molecular-weight EGFR tyrosine kinase inhibitors, Subject index Cancer (Continued mechanisms of action, 37 monoclonal anti }b oalaes s, 73/ optimal biological dose with other targeted therapies, 37 rational biomarker development inti-HER2 agents, 386- peptidomimetics zumab, 389 aptamers, 390 HEI 389 1A—paclitaxel molide 1ucleotides iiccaall ardaloloxicily cnetr no( t menopausal Carmustine, causing chemotherapy-related lun CD5, relevance in origin of ll chronic lymphocy CD23, soluble, serum level as prognostic marker leukemia ( polyethylene glycol-coated liposomal I doxorubicin, 89-90 716 Subject index nnn eee ee arner mpm Chemotherapy (Continued Chemotherapy extravasation taxanes, 86-89 initial management, 141 thalidomide, 91 pharmacologic management, 141-142 topoisomerase lin prevention, 139-140 vinorelbine, 91 surgery, 142 gastrointestinal toxicity Chemotherapy-induced peripheral neuropathy candidiasis, 114 clinical challenges in diagnosis and quantification, constipation, 114 clinical diagnostic features, 20-21 diarrhea, 114 clinical features associated with therapeutic agent Abraxane, 27 bortezomib, 29 carboplatin, 24, 27-28 malabsorption, 113-114 cisplatin, 24, 27-28 mucositis, 1 12- Lid Cremophor EL, 26-27 nausea and vomiting, 106-112 cytarabine, hepatotoxicity antimetabolites, 53- antitumor antibiotics oxaliplatin, 24-2 biologic response modifiers combination chemotherap\ paclitaxel procarbazine, 2 DNA covalent binding thalidomide, 2 hepatic veno-occlusive disease a ] a vinca alkaloids, 28-29 hormonal agents, dY me common and serious clinical problem, 23-24 microtubdule-tar design and endpoint considerations for clinical trials, 42-43 neous antineop diagnostic classification, 21-23 supportive care agent evaluation methods for, selection, standardization, and reliability deter- target-specific antineoplastic agent mination topoisomerase inhibitors, 5 patient-based methods, 36-39 physician-based methods, 33-36 quantitative sensory tests and electrophysiologic measurements in antimetabolites, 100-101 combination with neurologic evaluations, 31-33 bronchospasm, 98 pathogenesis and pathophysiology, 18-20 cytotoxic antibiotics, 98-100 prevention and treatment inflammatory interstitial pneumonitis, 98 amifostine, 40-41 microtubule inhibitors calcium/magnesium infusions, 42 miscellaneous agents, carbamazepine, 41-42 pleural effusions gabapentin, 41 pulmonary edema glutamate, 41 small molecule glutamine, 41 myelotoxicity glutathione, 41 anemia, nerve growth factor and analogs, 39-40 I avocept, 42 Chlorambucil, chemotherapy-related toxicity of hepatotoxicity, 52 lung injury, 101 antimetabolites Chromophobe renal cell carcinoma, pathology of, 537 evaluation of renal function Chromosome 11q abnormalities, in Richter’s syndrome in chronic lympho- platinum compounds, 69-7 cytic leukemia, 251 risk factors, 68-69 Chronic lymphocytic leukemia, 149 vascular toxicity angiogenesis in, 176-177 Budd-Chiari syndrome, 124 abnormal, therapeutic targeting, 180-181 capillary-leak syndrome, 128 prognostic implications, 179-180 hheyppaottiec nsvieonno -oacncdl uhsyipveer tednisseiaosne,, 1122a e2 -124 angiogenic cytokines in, biologic implications, 17 8-17/9 autoimmunity in leukocytoclastic vasculitis, 128 clinical features, 231] myocardial ischemia and infarction pathogenesis, 231-233 palmar-plantar erythrodysesthesia, 128 t reatment, 233-236 pathogenesis of, 128-129 B-cell, see B-cell chronic lymphocytic leukemia pulmonary veno-occlusive disease, 12 correcting immune defects in, 221-222 Raynaud’s phenomenon, 124 epigenetics in retinal-vessel toxicity, 128 aberrant promoter hypermethylation, 161-162 thrombosis and thromboembolic complications, 126-127 DNA methylation, 162-163 thrombotic microangiopathic syndrome, 125-126 genome-wide and gene-specific hypomethylation, 160-161] traditional, 408 therapy, 163 v neoadjuvant endocrine therapy, for locally advanced breast cancer, 652 familial, see Familial chronic lymphocytic leukemia 653 frontline therapy for v ovarian ablation and suppression, in premenopausal women with breast alemtuzumab, 204 cancer, 659 alkylating agent-based, 203 Subject index sss Chronic lymphocytic leukemia, 149 (Continued ) Clone cells, in b-cell chronic lymphocytic ]l euk| emia, 15<2 chemoimmunotherapy, 206 Clonidine, for menopausal vasomotor symptoms in breast cancer indications, 203 69090 prognostic factors for treatment response, 206-207 -MET, as ta} rget of rreennaall cell ] carcii nom+a tthheerraapyn, 5 592 purine analogue with alkylating agent, 205-206 -MYC oncogene, TMPyP4 inhibition via G-quadruplex silencer elet purine analogues, 203-204 368. 498-510 rationale approach and objectives, 202-203 relation to oncogenesis, 499 residual disease, 207 Coagulopathy, associated w rituximab, 204-205 Cognition, effects of aromatase inhibitors on, 69 infections in ol1]l ecttii ng d}u ct carcinoma, renal, pastt}h olo] gyy of+,+ ~5 23 8-5~32 9 cell-mediated immunity and, 241 ombination chemotherapy complement defects and, 241 ily Ol) ,t hypogammaglobulinemia and, 240-241 omplement defects, association with infections neutrophil and phagocytic defects, 241-242 leukemia, 24] pathogenesis, 240 one dysfunction, cancer-associated, 284 prevention, 246-247 onstipation, chemotherapy-related spectrum of, 242-245 oOr iicosterolds miRNAs in in cancer » cchheomm th1 erer alw n association with prognostic factors and progression, and cytotoxic drugs differential expression, 169-170 cytic leukemia germ-line mutations, 170-171 ranial irradiation miR-15a and miR-16-1 genes in CD5* cells, 168 ranial nerves, paraneoplasti model of cancer initiation and progression, 171-172 bilateral diffuse uveomel and post-translational inhibition of BCL2, 171 cancer-associated cone regulatory functions, 168-169 melanoma-associate monoclonal antibody therapy, 224, 226 yptic neuropathy neovascularization in, prognostic implications, 179- visual, 282-284 relapsed, see Relapsed chronic lymphocytic leukemic remophor El Richter’s syndrome in diagnostic evaluation, 252-253 etiology and oncogenesis, 250-2 incidence, 252 prognostic factors, 253 symptoms and signs, clophosphamic treatment, 253-254 hemotherapy- risk stratification in clinical staging systems, 186 evaluation of autologous and allogeneic stem cell transplantation, 192- 193 genetic parameters, 187-191 markers of tumor burden, 186-187 prognostic factors, 186-191 soa -arly-stage chronic lymphocytic leukemia, 191-192 progression In early-stage Chronic lymphocytic leukemia, < response to treatment and survival in advanced-stage chronic lympho- cytic leukemia, 192 serum parameters, 187 serum/plasma levels of angiogenic factors in, 176-177 stem cell transplantation and graft-versus-leukemia effect, 22 stromal cells in, biologic implications, 178-179 vaccine development fot altered tumor as antigen source, 22 dendritic cells, 223-224 gene therapy, 224 idiotype, 222 other tumor antigens, 222-223 trioma cells, 224 VEGF in autocrine pathway, 177-178 biologic implications, 178-179 Cigarette smoking, and renal cell carcinoma, 529 CIPN, see Chemotherapy-induced peripheral neuropathy Cisplatin, chemotherapy-related toxicity of CIPN, clinical features of, 24 v carboplatin, 27-28 renal toxicity, 69-70 72 ) Cladribine TD ermatolo] gic toxWiicciityy chemotherapy-related hepatotoxicity of, 55 antimetabolites, 9 and increased infection risk in chronic lymphocytic leukemia, 243 bortezomib, 93-94 Clear cell renal cell carcinoma, pathology of, 534-535 cetuximab, 93 Subject index a ————————————————— ————— Enteritis, chemotherapy-related, 114-115 Epidermal growth factor receptor, as target of renal cell carcinoma therapy 39] Epidermal growth factor receptor-targeting agents, see Anti-EGFR Epidural spinal cord compression due to leukemia and lymphoma, 343 metastatic, management ol historical review, 307-308 radiotherapy, 310 randomized trials, 308-309 surgery, 309-310 time to motor weakness as prognostic Epigenetics in chronic lymphocytic leukemia aberrant promoter hypermethylation cancer therapy, 163 DNA methylation, 162-163 genome-wide and gene-specific hypomethylation cross-talk between histone modifications and DNA m deregulation in cancer, 158-159 DNA methylation, 157-159 tp ost-tt ranslalat ionanall mo, difliif catioionn ol h+i] stonnNe Epirubicin, cardiotoxicity of, 4 Epithelial tumors, of the kidney, see Renal epitl Epothilones, for targeted cancer therapy, 428-430 Epstein-Barr virus, in Richter’s syndrome in ch 251-252 Erlotinib causing chemotherapy-related lung injury for targeted cancer therapy, 373-375 Erythropoiesis stimulators, in cancer chem Erythropoietin recombinant, in cancer chemothe as target of renal cell carcinoma therapy Esophagitis, chemotherapy-related, 114 Estrogen receptor, in breast cancer, 631-6 activation in the absence ol estrogen, 6 troygeenn thl erapy, for breast cancer, hormesis in, 709 Etoposide, chemotherapy-related toxicity of CIPN, clinical features of, 29-30 hepatotoxicity, 57 1emotherapeutic agents management, 14] pharmacologic management prevention, 139-140 ilial chronic lymphocytic leukemia iaracteristics of, 195-197 d DNA methylation, 162 models of, 1 genetic predisposition to, 195 d germ-line mutations of miRNAs, 170-171 oreservation in premenopausal breast cancer patients, 664-669 Filgrastim, causing chemotherapy-related lung injury, 103 Flavopiridol, for fludarabine-refractory chronic lymphocyti 215 Fludarabine chemotherapy-related hepatotoxicity of, 55 for fludarabine-refractory chronic lymphocytic leukemia and cyclophosphamide and rituximab, 213-214 Endocrine therapy, see Hormonal therapy or pentostatin with cyclophosphamide, 212-213 Endomyocardial biopsy in monitoring of anthracycline cardiotoxicity, 6 and increased infection risk in chronic lymphocytic leukemia, 242-243 Subject index Fludarabine monophosphate, causit hemotherapy-related lung injury 100 Fludarabine-refractory chronic | new antibodies and biologic the new v etelll ective targetec flavopiridol, 214-215 lenalidomide, 215 all molecules it rd treatment Campath-1H) tive nucleoside analogs fludarabine, cyclophosphamide, and ri fludarabine or pentostatin with cyclophosp hi1aiotg h-dose methylprednisolonen rituximab Gene-moalle Genomic Genomics cchnee mm i miRNAs associall X- 16-1 genes in CD5 model of cancer Subject index Immunoglobulin, intravenous, for autoimmunity in chronic lymphocytic leukemia, 234 Immunoglobulin receptors, in b-cell chronic lymphocytic leukemia antigen and progression, 152 antigenic element and, 151-152 circulating leukemia-like cells, 152-153 Immunoglobulin therapy, for infection prevention in chronic lymphocytic leukemia, 246 Immunophenotype of B-cell prolymphocytic leukemia, 2 of T-cell prolymphocytic leukemia Immunosuppression long-term, in bone marrow and stem cell transplantation, neurotoxicity associated with, 356-357 tumor-mediated, in renal cell carcinoma, reversal of immature myeloid cells, 621-622 regulatory T cells, 622 Immunotherapy, adjuvant, for renal cell carcinoma, 578 Infections associated with lymphoma and leukemia, 345 chronic lymphocytic leukemia cell-mediated immunity and, 241 complement defects and, 241 hypogammaglobulinemia and, 240-241 utrophil and phagocytic defects and, 241-242 pathogenesis, 240 prevention o! antimicrobial prophylaxis, 246-247 immunoglobulin therapy vaccination, 246 ctrum ol alemtuzumab, 24 alkylating agents, 2 chemoimmunotherapy cl] adribiihnien,e 224433 ; vmpho 549-356St ) transmitted itial pneumonitis myopatnies, paraneop es, as PKC modulat CIPN, c features Ol 109.-2H hepatotoxicity, 58 1 cell1 ] Carrcciinn neurotoxicity rapy-related toxicity of hepatotoxicity, 58 lung injury, 103 for renal cel adjuvant therapy erapy for metastatic carcinoma, 583-586 Interleukins, in cancer chemotherapy, neurotoxicity of, 330 rathecal biologic agents, antibodies, and immunoconjugates, for neoplas- tic meningitis, 320 Intrathecal chemotherapy, for neoplastic menir newer and investigational, 319-320 injury, 102-1 Intravenous immunoglobulin, for autoimmunity in chronic lymphocytic Immunity, cell-mediated, association with infections in chronic lymphocytic leukemia, 234 leukemia, 241 Investigational agents, for multitargeted cancer therapy Immunoconjugates, intrathecal, for neoplastic meningitis, 320 mTOR inhibitors, 413-414